Literature DB >> 24934760

Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent.

Geraldo B Silva Junior1, Ana Patrícia F Vieira, Amanda X Couto Bem, Marília P Alves, Gdayllon C Meneses, Alice M C Martins, Sonia M H A Araújo, Alexandre V Libório, Elizabeth F Daher.   

Abstract

BACKGROUND: Renal abnormalities are often seen in sickle cell disease (SCD).
OBJECTIVE: To investigate the role of hydroxycarbamide as a protective agent in sickle cell nephropathy.
SETTING: Patients with SCD followed at a Hematology outpatients clinic.
METHODS: Prospective study with 26 SCD patients. Renal function evaluation was performed and a comparison between patients and control group was done. Patients using hydroxycarbamide were compared to those not taking this drug. MAIN OUTCOME MEASURE: Effect of hydroxycarbamide on renal function.
RESULTS: Patients mean age was 32.1 ± 9.9 years, and 16 (61 %) were males. Glomerular hyperfiltration was found in nine patients with SCD (34.6 %). GFR < 60 mL/min/1.73 m² was observed in three cases (11.5 %). Microalbuminuria (30-300 mg/day) was found in seven cases (27 %) and macroalbuminuria (>300 mg/dia) in one patient (3.8 %). All patients had urinary concentrating deficit, and inability to acidify urine was found in ten cases (38.4 %). The comparison of patients according to the use of hydroxycarbamide showed lower levels of serum creatinine in those using the drug (0.6 ± 0.1 vs. 0.8 ± 0.3 mg/dL, p = 0.03), as well as lower levels of 24 h-proteinuria (226 ± 16 vs. 414 ± 76 mg/dL, p = 0.0001), but not microalbuminuria (79 ± 15 vs. 55 ± 86 mg/dL, p = 0.35).
CONCLUSION: SCD is associated with important renal abnormalities. Hydroxycarbamide seems to protect kidney function in SCD by decreasing proteinuria but not microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24934760     DOI: 10.1007/s11096-014-9955-4

Source DB:  PubMed          Journal:  Int J Clin Pharm


  18 in total

1.  Renal function in sickle cell anemia. A case report and review of the literature.

Authors:  A P CROSLEY; W H STRICKLAND
Journal:  J Natl Med Assoc       Date:  1961-01       Impact factor: 1.798

2.  [Epidemiology of sickle cell disease hospital admissions in Brazil].

Authors:  Monique Morgado Loureiro; Suely Rozenfeld
Journal:  Rev Saude Publica       Date:  2005-12-07       Impact factor: 2.106

Review 3.  Complications associated with sickle cell trait: a brief narrative review.

Authors:  Geoffrey Tsaras; Amma Owusu-Ansah; Freda Owusua Boateng; Yaw Amoateng-Adjepong
Journal:  Am J Med       Date:  2009-04-24       Impact factor: 4.965

4.  Renal tubular dysfunction in sickle cell disease.

Authors:  Geraldo B Silva Junior; Ana Patrícia F Vieira; Amanda X Couto Bem; Marília P Alves; Gdayllon C Meneses; Alice M C Martins; Talita R Sanches; Lúcia C Andrade; Antonio C Seguro; Alexandre B Libório; Elizabeth F Daher
Journal:  Kidney Blood Press Res       Date:  2014-01-28       Impact factor: 2.687

5.  Proteinuria in adult Saudi patients with sickle cell disease is not associated with identifiable risk factors.

Authors:  Aamer Aleem
Journal:  Saudi J Kidney Dis Transpl       Date:  2010-09

Review 6.  Sickle-cell disease.

Authors:  David C Rees; Thomas N Williams; Mark T Gladwin
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

Review 7.  New insights on pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell nephropathy.

Authors:  Geraldo Bezerra da Silva; Alexandre Braga Libório; Elizabeth De Francesco Daher
Journal:  Ann Hematol       Date:  2011-09-08       Impact factor: 3.673

8.  Hydroxyurea use in sickle cell disease: the battle with low prescription rates, poor patient compliance and fears of toxicities.

Authors:  Amanda M Brandow; Julie A Panepinto
Journal:  Expert Rev Hematol       Date:  2010-06       Impact factor: 2.929

9.  Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia.

Authors:  Banu Aygun; Nicole A Mortier; Matthew P Smeltzer; Barry L Shulkin; Jane S Hankins; Russell E Ware
Journal:  Am J Hematol       Date:  2012-12-17       Impact factor: 10.047

10.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

View more
  2 in total

1.  A predictable but life-threatening complication of hydroxyurea in a patient with sickle cell anaemia: an experience learned from a Jehovah's Witness.

Authors:  Aung Myint Tun; Ei Ei Naing; Nay Min Tun; Elizabeth Guevara
Journal:  BMJ Case Rep       Date:  2015-09-30

2.  Computer Algorithm-Based Hydroxyurea Dosing Facilitates Titration to Maximum Tolerated Dose in Sickle Cell Anemia.

Authors:  Mahogany Oldham; Anna Conrey; Corinne Pittman; Cameron Fisher; Simone Hargrett; Kamille West; Mary Jackson; Staci Martin; Matthew M Hsieh; Neal Jeffries; Mihailo Kaplarevic; Dachelle Johnson; Purevdorj Olkhanud; Courtney D Fitzhugh
Journal:  J Clin Pharmacol       Date:  2020-07-16       Impact factor: 2.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.